As you may know, a small group of the New York investors (about 30 of us) contacted each other and recently got together for a drink (or two) and a discussion. Most of us brought our check books. If, as a group, we liked what our pooled information told us, we would each write a check.
We talked about everything we knew....from felony charges for a Texas Fisherman who pumps gas for a living to the reason why the volume was in the millions and the pps dropped below 2 cents a few weeks ago
The following is a brain storming summary of some of our thoughts summarized and put together. Again...it is hard to say any of this is fact. Perhaps it should simply be thought of as opinion, and do your own DD when you invest. IF NOTHING ELSE, those of you holding an investment in Baltia should be able to rest a little more easily at night.......
3 hours. Good stuff.
Manuals approval is well under way. From what we pieced together, from where we know we are in the process, we estimated....4 to 6 weeks. We figured the PRs would start rolling middle to end of July, and the bird would arrive middle to end of August (we need her here to do evacuation exercises). Revenue flights should begin in November, let's say before the end of 2012 to be safe. Remember...first month will be just 1 flight per week.
Those with experience in the airline industry...and believe me, I met quite a few (some with 35 years +!)...could not stress enough the significance of the comments letter from the FAA. Baltia has been working towards that letter for 2 1/2 years, and apparently the last time the FAA gave out such a letter was 2006...and that was before the current and more stricter regulations came into effect.
At the conclusion of the meeting, those of us who could, put "our money where our mouths are". Minimum, $10,000. I heard someone mention $40,000, someone else mentioned $100,000. Rest assured...Baltia's bank account is well into the 6 digits.
Baltia is closer than ever to getting through that first gate. Things should start getting very exciting pretty soon. I am personally counting on the last 1/2 of 2012 to be quite intense.............
As you may know, a small group of the New York investors
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Huawei Introduces Innovative Wearables for Enhanced Connectivity
Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...
Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained
Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...
Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group
Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...
Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now
Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...
Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance
Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...
Continue Reading